Core Viewpoint - Kyushu Tong (600998.SH) announced that its subsidiary, Beijing Jingfeng Pharmaceutical Group Co., Ltd., received approval from the National Medical Products Administration for the drug registration certificate of Isopropamide Iodide Injection, indicating a significant development in its product portfolio [1] Group 1 - The approved drug, Isopropamide Iodide Injection, is an antihistamine used for treating skin and mucosal allergies, motion sickness, and as an adjunct treatment before and after anesthesia and surgery [1] - The drug also serves to prevent and treat radiation sickness or drug-induced nausea and vomiting, highlighting its therapeutic versatility [1]

Core Viewpoint - Kanghong Pharmaceutical (002773.SZ) has received the Drug Registration Certificate for Brexpiprazole Tablets from the National Medical Products Administration, indicating regulatory approval for the treatment of schizophrenia [1] Group 1 - The Drug Registration Certificate numbers are 2025S03922 and 2025S03923 [1] - Brexpiprazole's mechanism of action in treating schizophrenia is not fully understood, but it may involve partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, along with antagonist activity at serotonin 5-HT2A receptors [1]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has received approval from the National Medical Products Administration for the drug registration certificate of heavy tartrate norepinephrine injection, which is intended for use in acute hypotensive states and as an auxiliary treatment for cardiac arrest [1] Group 1 - The heavy tartrate norepinephrine injection is used to restore blood pressure in acute hypotensive states [1] - It can also assist in the treatment of cardiac arrest and maintain blood pressure after resuscitation [1] - The product serves as an auxiliary treatment for shock due to insufficient blood volume, helping to temporarily maintain cerebral and coronary perfusion until volume resuscitation takes effect [1] Group 2 - The heavy tartrate norepinephrine injection has been classified as a Class 3 chemical drug and has passed the consistency evaluation [1]

Core Viewpoint - The company TianKang (301263.SZ) announced that its wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd. (referred to as "Huabo Kaisheng"), has received a drug registration certificate from the National Medical Products Administration for Finasteride and Tadalafil Capsules, making it the first company in China to obtain this certification for this drug combination [1]. Group 1 - Huabo Kaisheng is the first company in China to receive a drug registration certificate for Finasteride and Tadalafil Capsules [1]. - The drug is a combination of Finasteride, a 5α-reductase inhibitor, and Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, specifically designed to treat symptoms of benign prostatic hyperplasia (BPH) [1]. - The combination of these two drugs provides a synergistic therapeutic effect, with Finasteride reducing prostate volume and alleviating urinary difficulties, while Tadalafil directly relieves lower urinary tract symptoms associated with BPH [1]. Group 2 - Tadalafil also has the added benefit of improving erectile function, addressing potential erectile dysfunction side effects that may arise from Finasteride treatment [1].

Core Viewpoint - The company has received approval for the registration certificate of Clomipramine Hydrochloride Tablets, which is used for the treatment of depression, enhancing its product line and market competitiveness [1] Group 1 - The subsidiary, Ningbo Tianheng Pharmaceutical Co., Ltd., has been granted the drug registration certificate by the National Medical Products Administration [1] - The approval of Clomipramine Hydrochloride Tablets will further enrich the subsidiary's product offerings [1] - The production and sales of the new product may be influenced by industry policies and market environment changes, leading to uncertainties regarding its impact on the company's performance [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug registration certificate of levofloxacin oral solution, indicating a significant advancement in its product portfolio [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted the drug registration certificate for levofloxacin oral solution [1] - Levofloxacin is classified as a third-generation fluoroquinolone antibiotic, which works by inhibiting bacterial DNA gyrase activity, thereby obstructing bacterial DNA replication [1] Group 2: Product Characteristics - Levofloxacin exhibits a broad antibacterial spectrum and strong antibacterial action, making it a valuable addition to the company's offerings [1]

Core Viewpoint - The company has received approval for the registration of Levofloxacin oral solution from the National Medical Products Administration, indicating a significant advancement in its product portfolio [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted the drug registration certificate for Levofloxacin oral solution [1] - Levofloxacin is classified as a third-generation fluoroquinolone antibiotic, which works by inhibiting bacterial DNA gyrase activity, thereby blocking bacterial DNA replication [1] Group 2: Product Characteristics - Levofloxacin exhibits a broad antibacterial spectrum and strong antibacterial action, making it a valuable addition to the company's offerings [1]

华纳药厂12月10日公告，公司近日收到国家药品监督管理局核准签发的硫酸镁钠钾口服用浓溶液《药品 注册证书》。硫酸镁钠钾口服用浓溶液适用于成人，用于任何需要清洁肠道的操作前的肠道清洁（如需 要肠道可视化的操作包括内镜、放射性检查、外科手术）。本品不用于治疗便秘。公司硫酸镁钠钾口服 用浓溶液按新注册分类化学药品4类获得药品注册证书，视同通过一致性评价。 ...

福安药业12月10日公告，公司全资子公司福安药业集团湖北人民制药有限公司收到国家药品监督管理局 签发的药品注册证书，药品名称为注射用硫酸艾沙康唑，注册分类为化药4类，规格为0.2g。该药品适 用于治疗成人患者侵袭性曲霉病和侵袭性毛霉病。截至目前，共有11家企业（含人民制药）通过一致性 评价或视同通过一致性评价。药品注册证书的获得将进一步丰富子公司产品线，提升市场竞争力，但受 行业政策、市场环境变化等因素影响，产品的生产、销售情况以及对公司业绩的具体影响存在不确定 性。 ...

Core Viewpoint - The company announced that its wholly-owned subsidiary, Jiangsu Shenhua Pharmaceutical Co., Ltd., has received the acceptance notice for the registration application of Lactulose Oral Solution from the National Medical Products Administration, indicating the product has entered the registration review stage [1] Group 1: Product Details - Lactulose Oral Solution is a laxative characterized by its quick, gentle, and effective action, with high safety, making it suitable for individuals with chronic or habitual constipation [1] Group 2: Regulatory Process - The acceptance of the drug registration application signifies that the product is now in the registration review phase, with completion time, approval results, and post-approval sales conditions remaining uncertain [1] Group 3: Financial Impact - The company stated that the registration application will not have a significant impact on its short-term performance [1]